The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Babson Diagnostics, crowned Medtech Company of the Year in 2024, now offers GLP-1 monitoring through its innovative fingertip blood tests. Patients on GLP-1 medications like Wegovy can pick up prescriptions and get comprehensive bloodwork in one pharmacy stop. This pea-sized sample panel tracks key metrics for safer, more effective therapy.
90 Day Fiancé's Kim Menzies has transformed her life, shedding 70 pounds with Semaglutide and embracing newfound confidence. From 260 to 190 pounds, she's sharing her journey of healthier habits and self-love. 'I used to despise shopping for clothes and now I love it!'
Amazon Pharmacy is streamlining GLP-1 access by adding Zepbound KwikPen to its same-day delivery service. This multi-dose device holds a full month's supply, addressing manufacturing bottlenecks and offering $299 cash-pay pricing—far below traditional $1,000 quotes. Integrated with Amazon One Medical, it provides personalized care for weight management and obstructive sleep apnea patients.
South Africa's Aspen Pharmacare is accelerating Mounjaro's rollout across sub-Saharan Africa after its explosive success at home, where the GLP-1 market tripled to $133.6 million. With over half the market share and $78.97 million in projected sales, this expansion tests rapid access to advanced weight-loss therapies. Here's how Aspen's KwikPen approval paves the way.
In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.
The launch of the first oral GLP-1 weight-loss drug, Wegovy pill, is sparking renewed interest among employees wary of injections. But as demand surges, employers face tough choices on coverage amid high costs and side effects. This guide outlines 4 key facts from industry experts to inform your benefits strategy.
With surging demand for GLP-1 drugs in India, the All India Organisation of Chemists and Druggists (AIOCD) has issued a strict reminder to its 12.4 lakh members: sell obesity and diabetic GLP-1 medications, including injectables, only against valid prescriptions from qualified practitioners. This comes as pharma giants like Eli Lilly promote awareness for proper treatment. Understand the implications for patients seeking Tirzepatide brands like Mounjaro and Zepbound.
A new Cambridge study reveals that after stopping GLP-1 drugs like Ozempic and Wegovy, patients regain nearly 60% of lost weight within a year, with appetite returning rapidly. Researchers modeled long-term trends showing about 75% regain over time, emphasizing the need for lifestyle support. This comprehensive guide breaks down the findings and what they mean for patients.
New research reveals GLP-1 medications like Ozempic may significantly elevate risks of bone disorders and tendon injuries. Analyzing nearly 150,000 patients, the study found 30% higher osteoporosis rates and 50% increased tendon rupture risks over five years. Experts urge bone density monitoring amid these findings.
